Filgotinib for children and teens with ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests if filgotinib, a pill for adults with ulcerative colitis, works in children and teenagers. It may help those whose current treatments are not working well enough or cause side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Weigh at least 33 pounds (15 kg).
- Have had ulcerative colitis for at least 3 months.
- Active disease with bleeding, frequent stools, and inflammation seen on a scope.
- Current treatments (like steroids, immunosuppressants, or biologics) have failed, caused problems, or you can't take them.
- Not had a previous Janus kinase inhibitor like tofacitinib or upadacitinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This trial studies whether transferring healthy stool bacteria into the gut (fecal microbiota transplantation, or FMT) can improve symptoms in children with ulcerative colitis. It may help by changing gut bacteria, especially for children who are newly diagnosed or who didn’t respond to standard treatments.
This trial tests filgotinib, a new medication that may help reduce joint swelling and pain in children and teens (ages 8–17) with polyarticular juvenile idiopathic arthritis—a type of childhood arthritis affecting multiple joints. You're eligible if your current arthritis medicines haven't worked well enough.
This trial is testing a new drug (a JAK inhibitor) for people with rare inflammatory diseases like Behçet's, myositis, or IgG4-related disease that hasn't improved with standard treatments. The goal is to see if it can help control symptoms and reduce inflammation.
This trial tests three different types of biologic medications to find which works best as a first treatment for moderate-to-severe ulcerative colitis.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.